Allink Biotherapeutics Secures $47 Million in Series A Extension Funding to Enhance Clinical Programs Allink Biotherapeutics announces successful completion of a $47 million Series A extension to accelerate the development of antibody-drug conjugates and other innovative therapies.

Allink Biotherapeutics Secures $47 Million in Series A Extension Funding to Enhance Clinical Programs #Shanghai #USA #biopharmaceuticals #ADC #Allink_Biotherapeutics

Allink Biotherapeutics Successfully Raises $47 Million in Series A Extension for Clinical Advancement Allink Biotherapeutics has completed a $47 million extension round of Series A funding to advance clinical programs and innovative platforms, enhancing their ADC technology development.

Allink Biotherapeutics Successfully Raises $47 Million in Series A Extension for Clinical Advancement #Shanghai #United_States #Clinical_Trials #Allink_Biotherapeutics #ADC_technology

Allink Biotherapeutics Raises $47M to Propel Clinical Advancements and Innovative Drug Platforms Allink Biotherapeutics, Inc. has successfully completed $47 million extension rounds of Series A, accelerating its clinical development efforts for unique antibody-drug conjugates.

Allink Biotherapeutics Raises $47M to Propel Clinical Advancements and Innovative Drug Platforms #Shanghai #USA #oncology #Allink_Biotherapeutics #ADCs

Allink Biotherapeutics Secures $47 Million in Series A Funding to Propel Clinical Programs Forward Allink Biotherapeutics has successfully raised $47 million in additional Series A funding led by Legend Capital and Meituan Long-Z Investment, aiming to escalate their clinical programs.

Allink Biotherapeutics Secures $47 Million in Series A Funding to Propel Clinical Programs Forward #Shanghai #USA #oncology #Allink_Biotherapeutics #ADCs

Allink Biotherapeutics Secures $42M to Enhance Bispecific Antibody and ADC Development Allink Biotherapeutics has successfully raised $42 million in Series A funding to further develop bispecific antibodies and ADCs in global markets.

Allink Biotherapeutics Secures $42M to Enhance Bispecific Antibody and ADC Development #USA #Beijing #Allink_Biotherapeutics #Lanchi_Ventures #ADC_technology

Allink Biotherapeutics Secures $42 Million Investment to Enhance Bispecific Antibody Development and Clinical Trials Allink Biotherapeutics has successfully raised $42 million in Series A funding, marking a significant step in advancing its bispecific antibody and ADC programs.

Allink Biotherapeutics Secures $42 Million Investment to Enhance Bispecific Antibody Development and Clinical Trials #China #Shanghai #Allink_Biotherapeutics #Lanchi_Ventures #Gaorong_Ventures